Controlled clinical trial comparing intra-incisional cephaloridine and Polybactrin Spray.
300 patients undergoing various operations were randomly allocated to receive, intra-incisionally, just before skin suture, either a solution of 1 g cephaloridine or Polybactrin aerosol. An equal number of patients were allocated to each group, and various factors likely to influence the incidence of wound infections were evenly distributed. 13 wound infections (9.8%) developed in the cephaloridine group and 28 (20.1%) in the Polybactrin group (p less than 0.02). In the former group, the infections were milder and there were 44 fewer patient-days of hospitalisation. The difference in infection rates for 'potentially contaminated and contaminated' operations was greater (p less than 0.01), in favour of cephaloridine. Other differences are discussed and some reasons for the superiority of cephaloridine over other agents (e.g., povidone-iodine, ampicillin) are advanced.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001414:Bacitracin / Q000008:administration & dosage* / Q000627:therapeutic use*; D002509:Cephaloridine / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008131:London; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000008:administration & dosage* / Q000627:therapeutic use*; D011112:Polymyxin B; D011113:Polymyxins / Q000008:administration & dosage* / Q000627:therapeutic use*; D012737:Sex Factors; D013530:Surgical Wound Infection / Q000453:epidemiology / Q000517:prevention & control*; D013997:Time Factors; D014947:Wounds and Injuries / Q000188:drug therapy
D004338:Drug Combinations; D011113:Polymyxins; D001414:Bacitracin; C001816:bacitracin zinc, neomycin sulfate, polymyxin B, drug combination; D009355:Neomycin; D011112:Polymyxin B; D002509:Cephaloridine